47
Participants
Start Date
December 14, 2022
Primary Completion Date
October 31, 2025
Study Completion Date
December 31, 2025
Hypericin
SGX302 is synthetic hypericin formulated as a 0.25% hypericin ointment or gel.
Placebo
Placebo ointment is identical to SGX302 ointment (color matched) but it does not contain hypericin.
RECRUITING
Therapeutics Clinical Research, San Diego
Lead Sponsor
Soligenix
INDUSTRY